FDA grants approval of Xolair (omalizumab) prefilled syringe formulation
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved 75 mg/0.5 mL and 150 mg/1 mL single-dose prefilled syringes (PFS) for Xolair ® (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications. (Source: Roche Investor Update)
Source: Roche Investor Update - October 1, 2018 Category: Pharmaceuticals Source Type: news
FDA Approves Genentech's Xolair (omalizumab) Prefilled Syringe Formulation
South San Francisco, CA -- September 28, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved 75 mg/0.5 mL and 150 mg/1 mL single-dose prefilled... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2018 Category: Drugs & Pharmacology Source Type: news
10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 27, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Real-life experience of Omalizumab in adult Cystic Fibrosis patients with allergic severe asthma and Allergic Bronchopulmonary Aspergillosis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 27, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Morning Break: DNA Risk Calculator; Xolair for Food Allergies; Med Students Ditch School
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 14, 2018 Category: Psychiatry Source Type: news
FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair ® (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies. (Source: Roche Investor Update)
Source: Roche Investor Update - August 13, 2018 Category: Pharmaceuticals Source Type: news
Study suggests similarity between biosimilar GBR 310 and omalizumab: Glenmark
Glenmark Pharma said that results from a study suggests similarity between biosimilar GBR 310 and the reference product omalizumab. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 26, 2018 Category: Pharmaceuticals Source Type: news
Impact of Omalizumab Treatment in Severe Allergic Asthma Impact of Omalizumab Treatment in Severe Allergic Asthma
A new study provides a clinical and cost analysis regarding the use of omalizumab in the treatment of severe asthma.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
Novartis' Xolair ® recommended in new global chronic urticaria guideline
A new global guideline on chronic urticaria (CU) recommends Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines[1],[2]. Xolair is the only licensed treatment option for CSU, a type of CU, for patients unresponsive to antihistamines[1]. (Source: World Pharma News)
Source: World Pharma News - March 6, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Longer Omalizumab Use Eases Itch From Chronic Hives Longer Omalizumab Use Eases Itch From Chronic Hives
The quality of life of patients with idiopathic urticaria improved when they stayed on the monoclonal antibody for 48 instead of 24 weeks, the XTEND-CIU study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2018 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Omalizumab cost effective for chronic spontaneous urticaria
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events
[9-26-2014] A U.S. Food and Drug Administration (FDA) review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug Xolair (omalizumab) than in those who were not treated with Xolair. As a result, we have added information about these potential risks to the drug label. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2018 Category: Drugs & Pharmacology Source Type: news
Tiotropium cost effective alternative to omalizumab
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2018 Category: Drugs & Pharmacology Source Type: news
HealthWatch: New Treatment To Help Kids With Multiple Food Allergies
BOSTON (CBS) – Doctors may soon have a new option to treat kids with multiple food allergies.
Researchers at Stanford University studied 48 children between the ages of 4 and 15 who have allergies to more than one food. They found that more than 80% of those treated with a combination of an asthma drug, Xolair, and an oral medication which helps block the body’s immune response, were able to eat at least two grams of two or more foods to which they were allergic.
The allergies included milk, eggs, wheat, soy, peanuts and tree nuts.
About 30% percent of people with food allergies are allergic to more than ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 13, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Syndicated Local Dr. Mallika Marshall Food Allergies Source Type: news
Omalizumab improves efficacy of oral immunotherapy for multiple food allergies
Combination allows more than 80 percent of children to safely consume at least two foods to which they were allergic. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 12, 2017 Category: American Health Source Type: news
